^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SAR444200
i
Other names: SAR444200
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sanofi
Drug class:
TCR modulator, GPC-3 inhibitor
Related drugs:
11ms
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=106, Recruiting, Sanofi | Trial completion date: May 2030 --> Dec 2030 | Trial primary completion date: May 2030 --> Dec 2030
Trial completion date • Trial primary completion date • Metastases
|
ALK (Anaplastic lymphoma kinase) • GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
Tecentriq (atezolizumab) • SAR444200
over1year
Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results (ESMO 2023)
Conclusions These preliminary results from the first two DLs suggest that SAR444200 is tolerable at the tested DLs in patients with advanced solid tumors. Dose escalation continues at this time.
Clinical • P1/2 data • Metastases
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
SAR444200
over1year
Dose Escalation and Expansion Study of SAR444200 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=106, Recruiting, Sanofi | Trial completion date: May 2029 --> May 2030 | Trial primary completion date: May 2029 --> May 2030
Trial completion date • Trial primary completion date • Metastases
|
GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
Libtayo (cemiplimab-rwlc) • SAR444200
2years
Dose Escalation and Expansion Study of SAR444200 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=106, Recruiting, Sanofi | Trial completion date: Feb 2028 --> May 2029 | Trial primary completion date: Feb 2028 --> May 2029
Trial completion date • Trial primary completion date
|
GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
Libtayo (cemiplimab-rwlc) • SAR444200
over2years
Dose Escalation and Expansion Study of SAR444200 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=106, Recruiting, Sanofi | Not yet recruiting --> Recruiting
Enrollment open
|
GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
Libtayo (cemiplimab-rwlc) • SAR444200
over2years
Dose Escalation and Expansion Study of SAR444200 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=106, Not yet recruiting, Sanofi
New P1/2 trial
|
GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
Libtayo (cemiplimab-rwlc) • SAR444200
Share via
